World's Best Scientists 2026 revealed!
Patrick J. Loehrer

Patrick J. Loehrer

D-Index & Metrics

Medicine

D-Index
101
Citations
37928
World Ranking
7971
National Ranking
4146

Overview

Patrick J. Loehrer is affiliated with Indiana University in the United States and specializes primarily in Medicine, with a significant focus on Oncology. Their research portfolio includes 168 publications within the broader medical field, and their work spans several related subfields including Oncology, Neurology, Epidemiology, Public Health, Environmental and Occupational Health, and Surgery.

The main topics of Loehrer's research cover a range of cancer-related and medical conditions including:

  • Myasthenia Gravis and Thymoma
  • Cervical Cancer and HPV Research
  • Global Cancer Incidence and Screening
  • Pituitary Gland Disorders and Treatments
  • Economic and Financial Impacts of Cancer
  • Advances in Oncology and Radiotherapy
  • Hepatitis B Virus Studies

Loehrer has contributed to a number of recent academic papers that highlight their diverse research interests. Notable recent publications include:

  • Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC), 2021, Journal of Clinical Oncology
  • Acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer: Results of a pilot randomized trial, 2022, Palliative Medicine
  • Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency, 2024, New England Journal of Medicine
  • COVID-19, Social Justice, and Clinical Cancer Research, 2020, JNCI Journal of the National Cancer Institute
  • Recommendations from the ASCO Academic Global Oncology Task Force, 2020, JCO Global Oncology

The scientist frequently publishes in leading medical journals. The venues where Loehrer has multiple publications include:

  • Journal of Clinical Oncology
  • JCO Global Oncology
  • Proceedings of IMPRS
  • Mediastinum
  • SSRN Electronic Journal

Among coauthors, Loehrer has collaborated extensively with colleagues such as Omenge Orang'o, Kapten Muthoka, Aaron Ermel, Darron R. Brown, and Rohan Maniar, with coauthoring counts ranging from 15 to 23 joint works each.

Loehrer has also contributed to the academic literature through book publications. One such work is titled Thymoma and Thymic Carcinoma: Diagnostic Imaging, Pathological Assessment, and Treatment Options, published in 2023 by Frontiers Media.

Best Publications

  • Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

    Leonard B. Saltz;Neal J. Meropol;Patrick J. Loehrer;Michael N. Needle

  • Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

    S D Williams;S D Williams;R Birch;R Birch;L H Einhorn;L Irwin;L Irwin

  • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    P J Loehrer;L H Einhorn;P J Elson;E D Crawford

  • Drugs five years later. Cisplatin.

    Patrick Loehrer;Lawrence Einhorn

  • Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

    Mario A. Eisenberger;Brent A. Blumenstein;E. David Crawford;Gary Miller

  • Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner

  • Pain and Treatment of Pain in Minority Patients with Cancer: The Eastern Cooperative Oncology Group Minority Outpatient Pain Study

    Charles S. Cleeland;René Gonin;Luis Baez;Patrick Loehrer

  • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    S B Saxman;K J Propert;L H Einhorn;E D Crawford

  • Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

    Patrick J. Loehrer;René Gonin;Craig R. Nichols;Tess Weathers

  • Pancreaticoduodenectomy: A 20-year experience in 516 patients

    C. Max Schmidt;Emilie S. Powell;Constantin T. Yiannoutsos;Thomas J. Howard

  • Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.

    L H Einhorn;S D Williams;P J Loehrer;R Birch

  • The development of non-germ cell malignancies within germ cell tumors : a clinicopathologic study of 11 cases

    Thomas M. Ulbright;Patrick J. Loehrer;Lawrence M. Roth;Lawrence H. Einhorn

  • Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

    C R Nichols;G Tricot;S D Williams;K van Besien

  • Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

    Bruce J. Roth;Robert Dreicer;Lawrence H. Einhorn;Donna Neuberg

  • Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

    C R Nichols;P J Catalano;E D Crawford;N J Vogelzang

  • Thymoma: State of the Art

    Charles R. Thomas;Cameron D. Wright;Patrick J. Loehrer

  • Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

    Patrick J. Loehrer;Kyungmann Kim;Seena C. Aisner;Robert Livingston

  • National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002

    Sidney Cohen;Bruce R. Bacon;Jesse A. Berlin;David Fleischer

  • Salvage Therapy in Recurrent Germ Cell Cancer: Ifosfamide and Cisplatin plus Either Vinblastine or Etoposide

    Patrick J. Loehrer;Richard Lauer;Bruce J. Roth;Stephen D. Williams

  • Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma

    Robert J. Motzer;Barbara A. Murphy;Jennifer Bacik;Lawrence H. Schwartz

Frequent Co-Authors

Lawrence H. Einhorn
Lawrence H. Einhorn Indiana University
Sunil Badve
Sunil Badve Emory University
Heather A. Wakelee
Heather A. Wakelee Stanford University
Thomas M. Ulbright
Thomas M. Ulbright Indiana University
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Frank C. Detterbeck
Frank C. Detterbeck Yale University
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
Constantin T. Yiannoutsos
Constantin T. Yiannoutsos Indiana University – Purdue University Indianapolis
Kathy D. Miller
Kathy D. Miller Indiana University
George W. Sledge
George W. Sledge Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of healthcare careers, both clinical and non-clinical. For those interested in administrative roles, medical billing and coding schools online offer flexible options to kickstart a healthcare support career, often with financial aid options available.

If you’re considering nursing, some programs offer easier entry points; for example, you may be wondering, do you have to take a teas test for lpn? Many schools are now removing standardized test requirements, making it easier than ever to begin your nursing journey.

For those seeking leadership opportunities, a health administration degree can be earned entirely online and at an accelerated pace—perfect for busy professionals aiming to move into management or executive roles in the healthcare sector.

Current registered nurses holding an associate’s degree can also advance their careers via asn to np programs, providing a streamlined bridge to achieve Nurse Practitioner status.

Best Scientists Citing Patrick J. Loehrer

Trending Scientists

Recently Published Articles